Federal Court Decision on Cannabis Approaching as Official Review Concludes

2026-08-10 politics

Washington, Sunday, 9 August 2026.
Following critical testimonies on product safety and chemistry, administrative briefs regarding marijuana’s move to Schedule III are due August 17, setting up crucial judicial challenges for federal policy.

Administrative Deadline and Judicial Oversight

The Drug Enforcement Administration’s administrative law proceedings regarding the proposed rescheduling of marijuana from Schedule I to Schedule III are entering a decisive phase as post-hearing briefs approach their submission deadline on August 17, 2026 [1]. Industry executives, including MMJ International Holdings CEO Duane Boise, are closely monitoring Administrative Law Judge Derek C. Julius, who is expected to issue a formal recommendation shortly after the briefs are submitted [1]. With today being August 9, 2026, there are 8 days remaining until the submission deadline, marking a critical countdown for stakeholders awaiting clarity on federal tax liabilities under Section 280E and institutional capital access [1][5]. The hearing record is now under review, with the ALJ tasked with determining if the evidence supports moving marijuana to Schedule III following the Attorney General’s April 2026 Rescheduling Order [1].

Scientific Testimony and Safety Concerns

During the hearings which concluded on July 15, 2026, significant testimony highlighted conflicts between scientific evidence and the government’s decision to classify state-distributed marijuana as Schedule III [1][3]. DEA scientist Dr. Luli Akinfiresoye provided testimony questioning marijuana’s reproducible chemistry, safety information, and evidence from well-controlled studies during the hearing [1]. Pain physician Dr. Kenneth Finn testified regarding the lack of federal control in state marijuana programs concerning dosing, labeling, and chemical composition compared to FDA-approved medicines [1]. Industry representatives assert that the testimony exposed fundamental tensions between the scientific evidence presented and the federal policy extending Schedule III treatment to marijuana distributed through qualifying state medical-marijuana programs [1]. Observers like Max Jackson, a former commercial cannabis cultivator, noted that no livestream or recording was allowed during the proceedings, requiring handwritten notes to document the debates around cannabis use disorder and research gaps [2].

Political Administration and Legal Challenges

The rescheduling effort is deeply intertwined with the current political administration, following Acting Attorney General Todd Blanche’s move in April 2026 to extend Schedule III treatment to state-licensed medical marijuana products [5]. On June 8, 2026, U.S. President Donald Trump formally nominated Todd Blanche to serve permanently as attorney general, solidifying the administration’s influence on the Department of Justice’s stance [5]. However, the Attorney General’s April 2026 Rescheduling Order is currently under judicial review in the U.S. Court of Appeals for the District of Columbia Circuit, challenged by MMJ International Holdings in case SAM Inc. v. Department of Justice [1]. MMJ, Inc. is also engaged in active federal litigation against the DEA regarding a bulk manufacturer registration application, highlighting the complex legal landscape surrounding bulk manufacturing and state-license pathways [1].

Market Reaction and Federal Discrepancies

Financial markets have reacted positively to the potential regulatory shifts, with the AdvisorShares Pure US Cannabis ETF (MSOS) surging 104% over the past year as of early June 2026 [5]. Despite market optimism, federal discrepancies remain evident in enforcement policies, such as the Transportation Security Administration’s updated policy announced around August 6, 2026, which clarified that marijuana remains a controlled substance under federal jurisdiction at airports [4]. Attorney Robby Terziyan noted that while TSA policy may update, changed policy and changed law are two very different things, warning travelers that airports operate under federal jurisdiction regardless of state laws [4]. Meanwhile, state-level complexities persist, with California’s treasurer calling Prop 64 a failure and Senators attempting to save hemp beverages through a new spending bill as reported in early August 2026 [6].

Sources

Cannabis Rescheduling DEA Hearing